StockData
Equillium, Inc. logo

Equillium, Inc. (EQ) company profile

EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.21+0.06 (+5.22%)

Close on Nov 17, 2026Market cap $76.72MP/E –Yield –

About Equillium

Pharmaceutical Preparations, SIC 2834

Equillium, Inc. is a biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. Its pipeline includes EQ504, an aryl hydrocarbon receptor modulator being developed for the treatment of ulcerative colitis and other gastrointestinal conditions, with potential expansion into inflammatory lung diseases. The company is also evaluating EQ302, an orally administered bi-specific inhibitor of IL-15 and IL-21 designed to address gastrointestinal disorders such as celiac disease. Equillium focuses on addressing unmet medical needs across gastroenterology, dermatology, and pulmonology.

The company conducts its operations in the United States, utilizing dedicated office and laboratory spaces to support its research and drug development activities. Its research efforts and strategic corporate operations are based in California, with presence in San Diego and La Jolla. Equillium's principal executive offices and corporate headquarters are located in La Jolla, California.

Summary of the business section of Equillium's latest annual report, written by StockData.

Company profile

Company

Legal name
Equillium, Inc.
Headquarters
La Jolla, CA
Address
2223 Avenida De La Playa, Suite 105 92037
Phone
(858) 412-5302
Employees
14, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
EQ
Exchange
Nasdaq
IPO date
Oct 12, 2018
Shares outstanding
63M, Aug 7, 2026
Public float
$7.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1746466
CUSIP
29446K106
ISIN
US29446K1060
FIGI
BBG00LSL8C10
Share class FIGI
BBG00LSL8C29
LEI
549300OC7SSPSNNGHE64
EIN
82-1554746

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel BradburyCHAIRMAN, Director3,711,995
Bruce D. SteelChief Executive Officer, Director3,711,995
Stephen ConnellyPresident and CSO762,025
Christine ZedelmayerSr. Vice President and COO62,586
Penny TomPrincipal Accounting Officer65,000
Jason A. KeyesChief Financial Officer126,633
Martha J. DemskiDirector23,799
Mark PruzanskiDirector23,799
Charles Douglas McDermottDirector23,799
Barbara TroupinDirector–
Bala S. ManianDirector23,799
Peter ColabuonoDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.26M$4.48M$2.40M$146–
FY2024$684.39K$754.07K$512.83K$71–
FY2023$1.35M$1.03M$806.38K$68–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payTotalvs. prior year
Bruce D. Steel
Chief Executive Officer
$519.23K$353.51K$3.02M$361.80K$4.26M+522%
Stephen Connelly, Ph.D.
President and Chief Scientific Officer
$455.17K$271.40K$1.78M$200.00K$2.70M+420%
Christine Zedelmayer
Chief Operating Officer
$441.29K$175.00K$1.29M$194.00K$2.10M+315%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 12, 2018
Offer price
$14.00
Securities offered
4,670,000
Gross proceeds
$65.38M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 10, 2019

“The initial public offering price of our common stock is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 14 employees, of which 13 were full-time employees, who were engaged in research and development activities, operations, finance, business development or administration.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?